Contemporary Pharmacologic Treatments for Spasticity of the Upper Limb After Stroke: A Systematic Review

Clinical Therapeutics

Volumn 32, Issue 14, 2010, Pages 2282-2303

  Olvey, Eleanor L ^a   Armstrong, Edward P ^a   Grizzle, Amy J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Botulinum toxin; Spasticity; Stroke

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; TIZANIDINE;

ACCIDENTAL INJURY; ARM; ASTHENIA; CONTROLLED CLINICAL TRIAL (TOPIC); DISABILITY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; HYPOTENSION; INJECTION SITE PAIN; MICTURITION; MULTIPLE CYCLE TREATMENT; NAUSEA; PAIN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANGE OF MOTION; REVIEW; SIDE EFFECT; SOMNOLENCE; SPASTICITY; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ANALOG SCALE; WEAKNESS; XEROSTOMIA;

BOTULINUM TOXINS; CLINICAL TRIALS AS TOPIC; HUMANS; MUSCLE SPASTICITY; PARASYMPATHOLYTICS; STROKE; TREATMENT OUTCOME; UPPER EXTREMITY;

EID: 79951816984     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.01.005     Document Type: Review

References (85)

1. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation 2010, 121:e46-e215. American Heart Association Statistics Committee and Stroke Statistics Subcommittee, [published correction appears in Circulation. 2010;121:e260].
2. Barker W.H., Mullooly J.P. Stroke in a defined elderly population, 1967-1985. A less lethal and disabling but no less common disease. Stroke 1997, 28:284-290.
3. Mayer N.H. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve Suppl 1997, 6:S1-S13.
4. Lundström E., Terént A., Borg J. Prevalence of disabling spasticity 1 year after first-ever stroke. Eur J Neurol 2008, 15:533-539.
5. Watkins C.L., Leathley M.J., Gregson J.M., et al. Prevalence of spasticity post stroke. Clin Rehabil 2002, 16:515-522.
6. Sommerfeld D.K., Eek E.U., Svensson A.K., et al. Spasticity after stroke: Its occurrence and association with motor impairments and activity limitations. Stroke 2004, 35:134-139.
7. Sheean G. Botulinum toxin treatment of adult spasticity: A benefit-risk assessment. Drug Safety 2006, 29:31-48.
8. O'Brien C.F. Treatment of spasticity with botulinum toxin. Clin J Pain 2002, 18(Suppl 6):S182-S190.
9. Baba Y., Osborne M.D., Wszolek Z.K., et al. Treatment of spasticity with botulinum toxin. Ortop Traumatol Rehabil 2004, 6:665-672.
10. Esquenazi A. Falls and fractures in older post-stroke patients with spasticity: Consequences and drug treatment considerations. Clin Geriatr 2004, 12:27-35.
11. BOTOX (onabotulinumtoxinA) [prescribing information] Accessed November 19, 2010. http://www.allergan.com/assets/pdf/botox_pi.pdf.
12. Dysport (abobotulinumtoxinA) [prescribing information] Accessed November 19, 2010. http://www.dysport.com/pdf/prescribinginformation.pdf.
13. Myobloc (rimabotulinumtoxinB) [prescribing information] Accessed November 19, 2010. http://www.myobloc.com/hp_about/PI_5-19-10.pdf.
14. Duncan P.W., Zorowitz R., Bates B., et al. Management of adult stroke rehabilitation care: A clinical practice guideline. Stroke 2005, 36:e100-e143.
15. Simpson D.M., Gracies J.M., Graham H.K., et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1691-1698. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
16. Information for healthcare professionals: OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), abobotulinumtoxinA (marketed as Dysport) and ribabotulinumtoxinB (marketed as Myobloc) US Food and Drug Administration, Accessed April 6, 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htm.
17. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med 2009, 6:e1000097. PRISMA Group.
18. Levels of evidence Oxford Centre for Evidence-Based Medicine, Accessed October 29, 2010. http://www.cebm.net/index.aspx?o=1047.
19. Sun S.F., Hsu C.W., Sun H.P., et al. Combined botulinum toxin type A with modified constraint-induced movement therapy for chronic stroke patients with upper extremity spasticity: A randomized controlled study. Neurorehabil Neural Repair 2010, 24:34-41.
20. Kaji R., Osako Y., Suyama K., et al. Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin 2010, 26:1983-1992. GSK1358820 Spasticity Study Group.
21. Suputtitada A., Suwanwela N.C. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil 2005, 27:176-184.
22. Smith S.J., Ellis E., White S., Moore A.P. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000, 14:5-13.
23. Yelnik A.P., Colle F.M., Bonan I.V., Vicaut E. Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: A randomised, double blind, placebo controlled study of botulinum toxin A. J Neurol Neurosurg Psychiatry 2007, 78:845-848.
24. McCrory P., Turner-Stokes L., Baguley I.J., et al. Botulinum toxin A for treatment of upper limb spasticity following stroke: A multi-centre randomized placebo-controlled study of the effects on the quality of life and other person-centred outcomes. J Rehabil Med 2009, 41:536-544.
25. Marco E., Duarte E., Vila J., et al. Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke?. A double-blind randomized clinical trial. J Rehabil Med 2007, 39:440-447.
26. Kong K.H., Neo J.J., Chua K.S. A randomized controlled study of botulinum toxin A in the treatment of hemiplegic shoulder pain associated with spasticity. Clin Rehabil 2007, 21:28-35.
27. Hesse S., Reiter F., Konrad M., Jahnke M.T. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: A randomized, double-blind, placebo-controlled trial. Clin Rehabil 1998, 12:381-388.
28. Gracies J.M., Lugassy M., Weisz D.J., et al. Botulinum toxin dilution and endplate targeting in spasticity: A double-blind controlled study. Arch Phys Med Rehabil 2009, 90:9e2-16e2.
29. Bhakta B.B., O'Connor R.J., Cozens J.A. Associated reactions after stroke: A randomized controlled trial of the effect of botulinum toxin type A. J Rehabil Med 2008, 40:36-41.
30. Bhakta B.B., Cozens J.A., Chamberlain M.A., Bamford J.M. Impact of botulinum toxin type A on disability and career burden due to arm spasticity after stroke: A randomised double blind placebo controlled trial [published correction appears in J Neurol Neurosurg Psychiatry. 2001;70:821]. J Neurol Neurosurg Psychiatry 2000, 69:217-221.
31. Bakheit A.M., Pittock S., Moore A.P., et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001, 8:559-565.
32. Brashear A., McAfee A.L., Kuhn E.R., Fyffe J. Botulinum toxin type B in upper-limb poststroke spasticity: A double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2004, 85:705-709.
33. Childers M.K., Brashear A., Jozefczyk P., et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004, 85:1063-1069.
34. Simpson D.M., Alexander D.N., O'Brien C.F., et al. Botulinum toxin type A in the treatment of upper extremity spasticity: A randomized, double-blind, placebo-controlled trial. Neurology 1996, 46:1306-1310.
35. Francisco G.E., Boake C., Vaughn A. Botulinum toxin in upper limb spasticity after acquired brain injury: A randomized trial comparing dilution techniques. Am J Phys Med Rehabil 2002, 81:355-363.
36. Brashear A., Gordon M.F., Elovic E., et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002, 347:395-400. Botox Post-Stroke Spasticity Study Group.
37. Lim J.Y., Koh J.H., Paik N.J. Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: A randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke 2008, 39:126-131.
38. Simpson D.M., Gracies J.M., Yablon S.A., et al. Botulinum neurotoxin vs tizanidine in upper limb spasticity: A placebo-controlled study. J Neurol Neurosurg Psychiatry 2008, 80:380-385. BoNT/TZD Study Team.
39. Bakheit A.M., Thilmann A.F., Ward A.B., et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000, 31:2402-2406.
40. Meythaler J.M., Vogtle L., Brunner R.C. A preliminary assessment of the benefits of the addition of botulinum toxin a to a conventional therapy program on the function of people with longstanding stroke. Arch Phys Med Rehabil 2009, 90:1453-1461.
41. Cousins E., Ward A., Roffe C., et al. Does low-dose botulinum toxin help the recovery of arm function when given early after stroke?. A phase II randomized controlled pilot study to estimate effect size. Clin Rehabil 2010, 24:501-513.
42. Lai J.M., Francisco G.E., Willis F.B. Dynamic splinting after treatment with botulinum toxin type-A: A randomized controlled pilot study. Adv Ther 2009, 26:241-248.
43. Chen J.J., Wu Y.N., Huang S.C., et al. The use of a portable muscle tone measurement device to measure the effects of botulinum toxin type a on elbow flexor spasticity. Arch Phys Med Rehabil 2005, 86:1655-1660.
44. Gordon M.F., Brashear A., Elovic E., et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004, 63:1971-1973. BOTOX Poststroke Spasticity Study Group.
45. Levy C.E., Giuffrida C., Richards L., et al. Botulinum toxin a, evidence-based exercise therapy, and constraint-induced movement therapy for upper-limb hemiparesis attributable to stroke: A preliminary study. Am J Phys Med Rehabil 2007, 86:696-706.
46. Slawek J., Bogucki A., Reclawowicz D. Botulinum toxin type A for upper limb spasticity following stroke: An open-label study with individualised, flexible injection regimens. Neurol Sci 2005, 26:32-39.
47. Stampacchia G., Bradaschia E., Rossi B. Change of stretch reflex threshold in spasticity: Effect of botulinum toxin injections. Arch Ital Biol 2004, 142:265-273.
48. Ivanhoe C.B., Francisco G.E., McGuire J.R., et al. Intrathecal baclofen management of poststroke spastic hypertonia: Implications for function and quality of life. Arch Phys Med Rehabil 2006, 87:1509-1515.
49. Meythaler J.M., Guin-Renfroe S., Brunner R.C., Hadley M.N. Intrathecal baclofen for spastic hypertonia from stroke. Stroke 2001, 32:2099-2109.
50. Lagalla G., Danni M., Reiter F., et al. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehabil 2000, 79:377-384.
51. Rousseaux M., Kozlowski O., Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. J Neurol 2002, 249:76-84.
52. Wang H.C., Hsieh L.F., Chi W.C., Lou S.M. Effect of intramuscular botulinum toxin injection on upper limb spasticity in stroke patients. Am J Phys Med Rehabil 2002, 81:272-278.
53. Pandyan A.D., Vuadens P., van Wijck F.M., et al. Are we underestimating the clinical efficacy of botulinum toxin (type A)?. Quantifying changes in spasticity, strength and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population. Clin Rehabil 2002, 16:654-660.
54. Reiter F., Danni M., Ceravolo M.G., Provinciali L. Disability changes after treatment of upper limb spasticity with botulinum toxin. Neurorehabil Neural Repair 1996, 10:47-52.
55. Rodriquez A.A., McGinn M., Chappell R. Botulinum toxin injection of spastic finger flexors in hemiplegic patients. Am J Phys Med Rehabil 2000, 79:44-47.
56. Brashear A., McAfee A.L., Kuhn E.R., Ambrosius W.T. Treatment with botulinum toxin type B for upper-limb spasticity. Arch Phys Med Rehabil 2003, 84:103-107.
57. Sampaio C., Ferreira J.J., Pinto A.A., et al. Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients. Clin Rehabil 1997, 11:3-7.
58. Viriyavejakul A., Vachalathiti R., Poungvarin N. Botulinum treatment for post-stroke spasticity: Low dose regime. J Med Assoc Thai 1998, 81:413-422.
59. Girlanda P., Quartarone A., Sinicropi S., et al. Botulinum toxin in upper limb spasticity: Study of reciprocal inhibition between forearm muscles. Neuroreport 1997, 8:3039-3044.
60. Gelber D.A., Good D.C., Dromerick A., et al. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke 2001, 32:1841-1846.
61. Panizza M., Castagna M., di Summa A., et al. Functional and clinical changes in upper limb spastic patients treated with botulinum toxin (BTX). Funct Neurol 2000, 15:147-155.
62. Elovic E.P., Brashear A., Kaelin D., et al. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil 2008, 89:799-806.
63. Bhakta B.B., Cozens J.A., Bamford J.M., Chamberlain M.A. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996, 61:30-35.
64. Caty G.D., Detrembleur C., Bleyenheuft C., et al. Effect of upper limb botulinum toxin injections on impairment, activity, participation, and quality of life among stroke patients. Stroke 2009, 40:2589-2591.
65. Miscio G., Del Conte C., Pianca D., et al. Botulinum toxin in post-stroke patients: Stiffness modifications and clinical implications. J Neurol 2004, 251:189-196.
66. Woldag H., Hummelsheim H. Is the reduction of spasticity by botulinum toxin a beneficial for the recovery of motor function of arm and hand in stroke patients?. Eur Neurol 2003, 50:165-171.
67. Ashford S., Turner-Stokes L. Management of shoulder and proximal upper limb spasticity using botulinum toxin and concurrent therapy interventions: A preliminary analysis of goals and outcomes. Disabil Rehabil 2009, 31:220-226.
68. Bakheit A.M., Fedorova N.V., Skoromets A.A., et al. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 2004, 75:1558-1561.
69. Cardoso E., Pedreira G., Prazeres A., et al. Does botulinum toxin improve the function of the patient with spasticity after stroke?. Arq Neuropsiquiatr 2007, 65:592-595.
70. Chang C.L., Munin M.C., Skidmore E.R., et al. Effect of baseline spastic hemiparesis on recovery of upper-limb function following botulinum toxin type A injections and postinjection therapy. Arch Phys Med Rehabil 2009, 90:1462-1468.
71. Shaw L., Rodgers H., Price C., et al. BoTULS: A multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technol Assess 2010, 14:1-113. BoTULS Investigators.
72. Bensmail D., Robertson J.V., Fermanian C., Roby-Brami A. Botulinum toxin to treat upper-limb spasticity in hemiparetic patients: Analysis of function and kinematics of reaching movements. Neurorehabil Neural Repair 2010, 24:273-281.
73. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964, 192:540-542.
74. Bohannon R.W., Smith M.B. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987, 67:206-207.
75. Francis H.P., Wade D.T., Turner-Stokes L., et al. Does reducing spasticity translate into functional benefit?. An exploratory meta-analysis. J Neurol Neurosurg Psychiatry 2004, 75:1547-1551.
76. Cardoso E., Rodrigues B., Lucena R., et al. Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: A meta-analysis. Arq Neuropsiquiatr 2005, 63:30-33.
77. Turkel C.C., Bowen B., Liu J., Brin M.F. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil 2006, 87:786-792.
78. Yablon S.A., Brashear A., Gordon M.F., et al. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: A pooled-data analysis of three clinical trials. Clin Ther 2007, 29:683-690.
79. Davis T.L., Brodsky M.A., Carter V.A., et al. Consensus statement on the use of botulinum neurotoxin to treat spasticity in adults. P&T 2006, 31:666-682.
80. Garces K., McCormick A., McGahan L., Skidmore B. Botulinum toxin A in the treatment of upper and lower limb spasticity: A systematic review of randomized controlled trials [Technology overview no 18] 2006, Canadian Coordinating Office for Health Technology Assessment, Ottawa, Accessed September 17, 2007. http://www.cadth.ca/media/pdf/352_botox_to_e.pdf.
81. van Kuijk A.A., Geurts A.C., Bevaart B.J., van Limbeek J. Treatment of upper extremity spasticity in stroke patients by focal neuronal or neuromuscular blockade: A systematic review of the literature. J Rehabil Med 2002, 34:51-61.
82. Elia A.E., Filippini G., Calandrella D., Albanese A. Botulinum neurotoxins for post-stroke spasticity in adults: A systematic review. Mov Disord 2009, 24:801-812.
83. Wissel J., Ward A.B., Erztgaard P., et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 2009, 41:13-25.
84. Montané E., Vallano A., Laporte J.R. Oral antispastic drugs in nonprogressive neurologic diseases: A systematic review. Neurology 2004, 63:1357-1363.
85. Chou R., Peterson K., Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: A systematic review. J Pain Symptom Manage 2004, 28:140-175.